Showing results (61-70 of 142) with videos related to

Sort By:
Pageof 15
Bone Marrow Transplantation|October 14, 2021
Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60Daniel A Pollyea, Amanda Winters, Christine McMahon, et al.
Haematologica|June 26, 2025
Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group AALL1331 trialLaura E Hogan, Teena Bhatla, Xinxin Xu, et al.
Investigational New Drugs|January 20, 2010
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancerQing Zhou, Daniel Gustafson, Sujatha Nallapareddy, et al.
Blood Advances|June 3, 2026
Carfilzomib plus induction chemotherapy in children with relapsed or refractory acute lymphoblastic leukemiaFranco Locatelli, Musa Karakukcu, Van Huynh, et al.
Pediatric Blood & Cancer|October 10, 2022
Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemiaMichael J Burke, David S Ziegler, Francisco Bautista, et al.
Haematologica|May 7, 2016
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphomaConnie Lee Batlevi, Yvette Kasamon, R Gregory Bociek, et al.
Investigational New Drugs|March 8, 2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumorsColin D Weekes, Muralidhar Beeram, Anthony W Tolcher, et al.
Experimental Hematology|May 29, 2019
CD123 CAR T cells for the treatment of myelodysplastic syndromeBrett M Stevens, Wei Zhang, Daniel A Pollyea, et al.
Investigational New Drugs|January 21, 2017
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week scheduleAntonio Jimeno, Manish R Sharma, Sergio Szyldergemajn, et al.
European Journal of Cancer (Oxford, England : 1990)|May 18, 2016
Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumoursDidier Frappaz, Sara M Federico, Andrew D J Pearson, et al.
Pageof 15